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deficiency, (2) after standard chemotherapy, (3) post- 
HSCT, (4) post-SOT, (5) inflammatory diseases/im- 
munosuppressive treatment, (6) HIV infection, (7) other 
groups. The recommendations will be outlined and are 
available on the RCPCH website. 
Conclusion: The introduction of the BPS should allow 
a consistent approach to immunisation of immuno- 
compromised children, and if this is confirmed at audit, 
will stimulate further research necessary to generate the 
solid evidence base that is required to support future 
recommendations. 
Infection in immunocompromised premature 
neonates are not associated with higher attributable 
mortality, but with neurologic sequelae 
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Slovak Republic 
Patients and methods: 246 cases were investigated to 
assess risk factors and outcome of infections, appearing 
in 36 neonates with very low birth weight (VLBW) 
<15OOg to other 210 neonates, appearing in 2 years in 
tertiary referral neonatal centre. 
Results: The analysis of types of cultures: blood cultures/ 
catheter. tips, showed that, the rate of bacteraemia/sepsis 
in <15OOg birth weight newborn infants (41.67% vs. 7.62, 
PsO.0001) was more higher than in those of >15OOg 
birth weight; umbilical swaps were more significantly 
observed in VLBW newborn infants than (40% vs. 
19.44%, PsO.029) <15OOg birth weight. According to 
the analysis of etiology there were differences between 
two groups for Klebsiella/Enterobacter infection rate, 
which showed higher rate of infection in VLBW infants 
(69.44 vs. 40.95, P<O.O027). According to the localisation 
of infection: bacteraemia/sepsis were more frequently 
prevalent and more significantly related to <15OOg birth 
weight newborn infants (36.11% vs. 5.71%, P10.0001) 
than >15OOg birth weight. Conjunctivitis (P10.0445), 
omphalitis (P10.031) were more frequently observed 
in >15OOg birth weight newborn infants, vice versa. 
Antibiotics used in the treatment of neonatal infection 
in both groups with significant univariate analysis 
were: penicillins (PsO.0237) meropenem (PsO.OOOl), 
ceftazidin (P10.02), ceftriaxon (P<O.o002), gentamicin 
(P<O.O0016), and netilmicin (P<O.OOOl) which were 
significantly and frequently observed in VLBW neo-nates. 
In an univariate analysis of mother’s risk factors, cerclage 
was more frequently observed (P%O.O005) in VLBW. 
Conclusion: The clinical significance of outcome were 
clear, since cure rates were logically higher among 
>15OOg birth weight newborn infants (98.57 vs. 88.89, 
P10.0099) than <15OOg birth weight, in term of death 
on underlying disease (overall mortality) (P10.0029). 
However PVL (P<O.O2), and IVH (IIIJIV.) (P10.0099) 
were significantly related to <15OOg birth weight new- 
born infants. 
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Background: One of the side effects reported on p- 
lactam antibiotic use is clinically significant bleeding. 
Among the mechanisms proposed for this adverse 
reaction was thrombocytopenia and platelets dysfunction. 
As of 1999 we use piperacillin/tazobactam as part of 
the empiric treatment for persumed sepsis. Since, pre- 
term infants are more prone to develop intraventricular 
hemorhage(IVH), some concerns have been raised 
as for the use of p-lactam antibiotics in this high risk 
population. 
Objective: To study the appearance of possible side 
effects of P/T use in term and preterm infants, parti- 
culary the incidence of IVH. 
Methods: Data from medical records were retrospectively 
collected from infants treated with P/T. Cranial ultra- 
sound (CUS) findings before, during and after the use of 
P/T were compared. The following side effects of the 
treatment were examined: clinical symptoms (allergic 
rash, gastrointestinal (GIT) symptoms, change in urine 
output, change in blood pressure) and blood tests 
(complete blood count, liver enzimes, bilirubin and 
creatinine). 
Results: During 1999-2001 a total of 165 episodes of P/T 
treatment were studied. In 55 episodes the treatment last 
for 5-14 days. Mean birth weight was 1690t900gr and 
GA was 31.7k4.7. CUS finding included 4 infants with 
IVH. All discovered during first 3 days of live and before 
the introduction of P/T. Low platelets(PLT) count was 
noticed in 38% of the patients(but was not related to P/T 
treatment). There were no evidence of allergic reaction, 
significant decrease in blood pressure, GIT symptomes 
or a change in blood test results. 
In 110 episodes the treatment last for 2-4 days, BW 
1300+550,GA 29.9k3.8. IVH was noticed in 15 (13.6%) 
infants all ocured before introducing P/T and 37 (33.6%) 
infants had low PLT(unrelated to the use of P/T). None 
of the above side effects were described. 
Conclusions: There was no increase in the rate of IVH 
with the treatment of P/T even in preterm infants with 
low PLT count. No other side effects occurred in this 
group of patients. More studies are required regarding 
the use of P/T in the neonate. 
